# A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients

> **NCT06115993** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ausper Biopharma Co., Ltd.** · enrollment: 129 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** AHB-137 injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06115993
- **Lead sponsor:** Ausper Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-03
- **Primary completion:** 2024-12-03
- **Final completion:** 2025-11-10
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06115993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06115993, "A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT06115993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*